The Utility of Micro-RNA

MicroRNAs have demonstrated roles in human development, where their expression can drive or maintain tissue phenotype. Correspondingly their aberrant expression is a significant driver of the pathophysiology of many chronic diseases including diabetes and cancer. miRNA's are recognised as being highly stable ex vivo and miRNA signatures can be obtained from samples with poor ribosome integrity number (RIN) values. When this is combined with their undisputed biological importance it makes miRNA’s attractive biomarker candidates for a wide range of applications.

The utility of miRNA provides a means to generate cost-effective, information-rich cell characterisation tools and biomarkers for use in the Bioprocessing, Cell and Stem Cell Therapy, and Drug Discovery and Development markets. Click to find out how our innovative miRNA products can help you

About Sistemic

Sistemic is a development-stage biomedical company focused on the analysis of the information content of microRNA and other non-coding RNAs for applications in the development of cell therapies and drug repositioning. Sistemic’s patented and proprietary technology platforms provide a novel way to apply the information content of miRNA’s to overcome key obstacles to creating clinically useful stem cell therapies.

Recent News

Season's Greeting from Sistemic

Release Date: December 24, 2013
The holiday season is upon us and Sistemic would like to take a moment to thank all of our collaborators, colleagues, clients and friends for a rewarding and productive year.
 
We hope you have an enjoyable holiday period and we hope to continue to work with you in 2014.
 

NHS Scotland and Sistemic Collaborate to develop novel early diagnostics for Diabetic sight loss

Release Date: October 25, 2013
 
Sistemic Limited, the Glasgow and Boston-based leader in the field of micro RNA (miRNA) analysis, today announced an agreement with NHS Scotland, supported by Health  Sciences Scotland to work together to in the area of Stratified Medicine to develop novel diagnostic biomarkers for the early detection of diabetic retinopathy and infective keratitis patients.